Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bolt Biotherapeutics, Inc. - Common Stock (NQ:BOLT)

5.760 +0.029 (+0.51%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bolt Biotherapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Bolt Biotherapeutics, Inc. Stockholder Notice: Robbins LLP Reminds Investors of the BOLT Class Action
From Robbins LLP
Via Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
From The Rosen Law Firm PA
Via GlobeNewswire
Shareholder Alert: Robbins LLP Informs Stockholders of the Class Action Filed Against Bolt Biotherapeutics, Inc. (BOLT)
From Robbins LLP
Via GlobeNewswire
BOLT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Bolt Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, A TOP RANKED LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – BOLT
From The Rosen Law Firm, P.A.
Via Business Wire
The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows
Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades. 
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
 
Via Benzinga
This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today
 
Via Benzinga
Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning! 
Via InvestorPlace
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023
BOLT stock results show that Bolt Biotherapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Pacira Appoints Frank D. Lee as Chief Executive Officer
From Pacira BioSciences
Via GlobeNewswire
Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu®
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
Via ACCESSWIRE
Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket
Gainers AERWINS Technologies Inc. (NASDAQ: AWIN) shares rose 90.2% to $0.2297 in pre-market trading. Aerwins Technologies is considering strategic alternatives for non-core operations including, not... 
Via Benzinga
Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers
From Bolt Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.